Chronic Kidney Disease

Reata Pharmaceuticals Inc. is seeking FDA approval for its drug bardoxolone methyl after results from phase 3 trials of the CARDINAL study showed patients with chronic kidney disease caused by Alport syndrome had a statistically significant improvement compared to placebo in mean retained eGFR.

Healio asked experts for their key takeaways from the ISCHEMIA and ISCHEMIA-CKD trials of invasive vs. conservative strategies in patients with stable ischemic heart disease.

WASHINGTON — Data presented at ASN Kidney Week suggested higher dietary protein intake is associated with increased risk for all-cause mortality and ESRD in patients with chronic kidney disease, with researchers also observing a decline in dietary protein intake with progressive loss of kidney function.

PHILADELPHIA — In stable patients with moderate or severe ischemia, an invasive strategy and a conservative strategy of optimal medical therapy yielded similar long-term CV outcomes, according to long-anticipated results of the ISCHEMIA and ISCHEMIA-CKD trials presented at the American Heart Association Scientific Sessions.

ATLANTA — The 2019 ACR gout guidelines call for treating patients to a target serum urate level of 6 mg/dL, a marked departure from the 2012 document, according to speakers at ACR/ARP 2019.

WASHINGTON — Results from the phase 3 OLYMPUS trial presented here show the investigational hypoxia-inducible factor prolyl hydroxylase inhibitor drug roxadustat significantly increased hemoglobin levels in patients with anemia and chronic kidney disease compared to those treated with placebo.

WASHINGTON — In a secondary analysis of the CREDENCE trial presented here at ASN Kidney Week, researchers focused on subgroups of different GFRs. They determined canagliflozin is safe and effective even for patients with eGFR of 30 mL/min/1.73m2 to less than 45 mL/min/1.73m2.

WASHINGTON — At ASN Kidney Week, Brad H. Rovin, MD, presented results of the NOBILITY trial, a phase 2 randomized, controlled study of obinutuzumab with mycophenolate and corticosteroids in patients with proliferative lupus nephritis.

WASHINGTON — Results from an ancillary study to the Vitamin D and Omega-3 Trial, known as VITAL, demonstrated no difference in eGFR reduction between patients with type 2 diabetes who were assigned to either supplementation or placebo. Data were presented at ASN Kidney Week and simultaneously published in JAMA.

WASHINGTON — Ritonavir-boosted protease inhibitors do not significantly impact creatinine-based GFR estimates compared with measured GFR for HIV-positive patients, according to data presented at ASN Kidney Week.